Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

Jorge Cortes, Apostolia M. Tsimberidou, Ricardo Alvarez, Deborah Thomas, Miloslav Beran, Hagop Kantarjian, Elihu Estey, Francis J. Giles*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML. Methods: MTA consisted of Mylotarg 9 mg/m2 intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m2 over 2 h i.v. on days 1 through 5, and topotecan 1.25 mg/m2 by continuous infusion i.v. on days 1 through 5. Results: A group of 17 patients (9 primary resistant, 8 relapsed) with AML or advanced myelodysplastic syndrome (MDS) received 20 courses of MTA. The median age of the patients was 55 years (20-70 years). Two patients (12%) achieved complete remission. The median overall survival was 8.2 weeks. Five patients (29%) developed grade 3/4 hepatic transaminitis, including one patient (6%) who died with hepatic venoocclusive disease. Conclusions: MTA was moderately effective and associated with significant toxicity in patients with refractory AML.

Original languageEnglish (US)
Pages (from-to)497-500
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume50
Issue number6
DOIs
StatePublished - Dec 19 2002

Keywords

  • Acute myeloid leukemia
  • Cytarabine
  • Mylotarg
  • Refractory
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia'. Together they form a unique fingerprint.

Cite this